Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06977217 · ClinicalTrials.gov registry record

Factors Associated With Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Non-LBBB ECG Pattern

A clinical trial of Heart Failure and Cardiomyopathies, sponsored by University of Rochester.

Active
Registry status
270
Enrollment target
1
Study location

NCT06977217: Active study of Heart Failure and Cardiomyopathies, sponsored by University of Rochester.

NCT06977217 is a study of Heart Failure and Cardiomyopathies that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 270 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06977217, a study of Heart Failure and Cardiomyopathies, is active but no longer recruiting, sponsored by University of Rochester.

ACTIVE NOT RECRUITING
Registry status
270 participants
Enrollment target
1
Study location

Study Summary

Cardiac resynchronization therapy with a defibrillator (CRT-D) in heart failure (HF) patients without left bundle branch block (non-LBBB) has been less beneficial to improve outcomes despite being a guideline indicated therapy, posing a significant treatment challenge. However, non-LBBB patients with echocardiography response to CRT-D have better outcomes, and pre-implant variables could predict response, identifying patients who benefit the most. In this study, we plan to enroll 270 HF patients with non-LBBB and guideline-indicated CRT-D implantation to validate our prior echocardiography predictor score, and to identify novel ECG and echocardiography predictors using conventional statistics and machine learning analysis. We will also assess the applicability of such a score for clinical outcomes of HF, ventricular arrhythmias, or death.

Primary Outcome

The primary endpoint of the study is a 25% or greater reduction in LV end-systolic volume 12 months after CRT-D implantation in HF patients with non-LBBB, analyzed by the central echocardiography core laboratory. Echocardiography outcomes will be assessed by sonographers blinded to patient characteristics or clinical outcomes to avoid bias.

Interventions

  • PROCEDURE CRT-D implantation

Study Locations (1)

New York

  • University of Rochester Medical Center - Rochester

Trial Details

FieldValue
Enrollment Target 270 participants
Start Date 2022-03-21
Est. Completion 2026-06-30
University of Rochester

636 total trials

What the registry record for NCT06977217 still lists

NCT06977217 is an observational study that tracks outcomes without assigning an intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (87% lower).

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which CRT-D implantation is the first listed.

NCT06977217 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06977217 about?

NCT06977217 is a clinical study titled "Factors Associated With Response to Cardiac Resynchronization Therapy in Heart Failure Patients With Non-LBBB ECG Pattern". Cardiac resynchronization therapy with a defibrillator (CRT-D) in heart failure (HF) patients without left bundle branch block (non-LBBB) has been less beneficial to improve outcomes despite being a guideline indicated therapy, posing a significant treatment challenge. However, non-LBBB patients wit...

What is the current status of trial NCT06977217?

This trial is currently active not recruiting. The enrollment target is 270 participants. The study started on 2022-03-21. Estimated completion is 2026-06-30.

What conditions does trial NCT06977217 study?

This clinical trial studies the following conditions: Heart Failure, Cardiomyopathies, Cardiac Resynchronization Therapy, Non-left Bundle Branch Block.

What interventions are being tested in trial NCT06977217?

The interventions under investigation include: CRT-D implantation (PROCEDURE).

Who is sponsoring clinical trial NCT06977217?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06977217 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06977217's enrollment target sits among peer trials

270 148th of 397 higher than 250 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00801489 · 270 participants · Phase 2

    Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • NCT04372485 · 270 participants · NA

    Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents

  • NCT04528446 · 270 participants

    The Impact of Glomerular Disorders on Bone Quality and Strength

  • NCT05215327 · 270 participants · Phase 2

    High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06977217, the US trial registry maintained by the National Library of Medicine. NCT06977217 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.